• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by PepGen Inc.

    4/9/24 4:49:47 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PEPG alert in real time by email
    SC 13G 1 b49244sc13g.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

     

     

    Under the Securities Exchange Act of 1934

     

     

    PepGen Inc.
    (Name of Issuer)
     
    Common stock, $0.0001 par value per share
    (Title of Class of Securities)
     
      713317105  
    (CUSIP Number)
     
    10 May 2022**
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    oRule 13d-1(b)

     

    xRule 13d-1(c)

     

    oRule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    ** Please note this constitutes a late filing due to a clerical oversight.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     1 
     

     

    CUSIP No . 713317105   Page 2 of 4

     

    1

    NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     

    Oxford Science Enterprises plc

    No I.R.S. Identification Number

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

    (a) o

    (b) o

    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    England, United Kingdom


    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED
    BY EACH
    REPORTING
    PERSON
    WITH:
    5 SOLE VOTING POWER 4,755,388
    6 SHARED VOTING POWER 0
    7 SOLE DISPOSITIVE POWER 4,755,388
    8

     

     

     

    SHARED DISPOSITIVE POWER

     

     

     

    0

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
    PERSON
    4,755,388
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES
    CERTAIN SHARES
    o
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 14.70%(1)
    12 TYPE OF REPORTING PERSON CO
    (1)Based on the quotient obtained by dividing (a) the aggregate number of common shares of common stock beneficially owned by Oxford Science Enterprises plc by (b) the 32,354,495 total common shares of common stock outstanding as of March 1, 2024, as reported by the Issuer on its Form 10-K filed on March 6, 2024.

     

     2 
     

     

    Item 1.

     

    (a) Name of Issuer: PepGen Inc.

    (b) Address of Issuer's Principal Executive Offices: 321 Harrison Avenue, Boston, MA 02142

     

    Item 2.

     

    (a) Name of Person Filing: Oxford Science Enterprises plc (the “Reporting Person”)

    (b) Address of Principal Business Office or, if none, Residence: 46 Woodstock Road, Oxford OX2 6HT, United Kingdom

    (c) Citizenship: England, United Kingdom

    (d) Title of Class of Securities: Common stock, $0.0001 par value per share

    (e) CUSIP Number: 713317105

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not Applicable.

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
           
      (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           
          If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:  

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a) Amount beneficially owned: 4,755,388

    (b) Percent of class: 14.70%

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 4,755,388

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 4,755,388

    (iv) Shared power to dispose or to direct the disposition of: 0

     

     3 
     

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not Applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

     

    Item 10. Certification

     

    Not Applicable.

     

     4 
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: April 9, 2024

     

     

      Oxford Science Enterprises plc
         
         
         
      By: /s/ Jim Wilkinson  
      Name: Jim Wilkinson  
      Title: Chief Financial Officer  
           

     

     

    5

     

     

     

    Get the next $PEPG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PEPG

    DatePrice TargetRatingAnalyst
    12/16/2024$3.00Neutral → Underperform
    BofA Securities
    7/31/2024$12.00Buy → Neutral
    BofA Securities
    12/21/2022$26.00Buy
    H.C. Wainwright
    More analyst ratings

    $PEPG
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by PepGen Inc.

      SCHEDULE 13G/A - PepGen Inc. (0001835597) (Subject)

      5/15/25 4:32:37 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by PepGen Inc.

      SCHEDULE 13G/A - PepGen Inc. (0001835597) (Subject)

      5/15/25 8:22:12 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PepGen Inc. (0001835597) (Filer)

      5/8/25 8:05:08 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PEPG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Mcarthur James G bought $13,550 worth of shares (10,000 units at $1.35), increasing direct ownership by 10% to 113,913 units (SEC Form 4)

      4 - PepGen Inc. (0001835597) (Issuer)

      4/22/25 7:01:12 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Mcarthur James G bought $47,725 worth of shares (41,500 units at $1.15), increasing direct ownership by 66% to 103,913 units (SEC Form 4)

      4 - PepGen Inc. (0001835597) (Issuer)

      4/9/25 7:40:15 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oxford Science Enterprises Plc bought $10,559,640 worth of shares (879,970 units at $12.00), increasing direct ownership by 23% to 4,755,388 units (SEC Form 4) (Amendment)

      4/A - PepGen Inc. (0001835597) (Issuer)

      4/9/24 5:24:38 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PEPG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Technical Officer Kasraian Kasra was granted 16,750 shares (SEC Form 4)

      4 - PepGen Inc. (0001835597) (Issuer)

      5/21/25 4:47:34 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Kasraian Kasra

      3 - PepGen Inc. (0001835597) (Issuer)

      5/21/25 4:00:51 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Mcarthur James G bought $13,550 worth of shares (10,000 units at $1.35), increasing direct ownership by 10% to 113,913 units (SEC Form 4)

      4 - PepGen Inc. (0001835597) (Issuer)

      4/22/25 7:01:12 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PEPG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

      PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies. "We are pleased to welcome Kasra to our executive leadership team," said James McArthur, PhD, President and Chief Executive Officer of PepGen. "He brings a rare depth of expertise in product

      5/20/25 7:00:00 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      – Reported positive DM1 patient data with mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg – – FREEDOM-DM1 data from 15 mg/kg cohort expected in the second half of 2025 – – CONNECT1-EDO51 data from 10 mg/kg cohort expected in the third quarter of 2025 – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2025. "Our EDO platform's unique ability to efficiently deliver oligonucleotides into the

      5/8/25 8:00:00 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference

      PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, PhD, President and CEO of PepGen, will present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 1:30pm ET. A webcast of the corporate presentation will be available on the "Events & Presentations" page within the Investors section of the PepGen website at https://investors.pepgen.com/. A replay of the webcast will be available on the PepGen website for 90 days following the presentation date. About

      4/2/25 4:05:00 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PEPG
    Financials

    Live finance-specific insights

    See more

    $PEPG
    Leadership Updates

    Live Leadership Updates

    See more

    $PEPG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $PEPG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

      – Significant mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg – – PGN-EDODM1 observed to have favorable emerging safety profile – – Conference call scheduled today at 8:00 a.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced initial positive clinical data from the 5 and 10 mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial investigating PGN-EDODM1 in myotonic dystrophy type 1 (DM1). "These results far exceeded our expectations for splicing correctio

      2/24/25 7:00:00 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

      – PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long-term extension portion of trial. Dosing of second cohort at 10 mg/kg is ongoing – – Four doses of PGN-EDO51 at 5 mg/kg achieved mean exon skipping levels of 2.15% after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean muscle-adjusted dystrophin level of 1.49%, a 0.70% increase from baseline, after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean absolute dystrophin level of 0.61%, a 0.26% increase from baseline, after three months of dosing – – Conference call scheduled for 4:30 p.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation

      7/30/24 4:02:00 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call

      BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, will report its fourth quarter and full year 2022 financial results and provide a corporate update on Thursday, March 23, 2023. PepGen's management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30pm ET. The event will be webcast live under the Events & Presentations section of the Investor Relations section of PepGen's website. A replay of the event will be archived

      3/16/23 8:00:00 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

      PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies. "We are pleased to welcome Kasra to our executive leadership team," said James McArthur, PhD, President and Chief Executive Officer of PepGen. "He brings a rare depth of expertise in product

      5/20/25 7:00:00 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen Announces Appointment of Two New Directors to its Board

      PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive experience in the life sciences to the Company. "We are thrilled to welcome Lisa and Mitch to our Board of Directors," said James McArthur, PhD, President and CEO of PepGen. "Lisa's proven ability to scale manufacturing for mid- to late-stage clinical trials and guide clinical-stage companies

      3/31/25 4:05:00 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development

      PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development (R&D), effective immediately. Dr. Streck will join the PepGen Executive Team and will be responsible for leading the R&D organization. "We are very pleased that Paul is joining PepGen at such an important time for the Company," said James McArthur, Ph.D., President and CEO of PepGen. "Throughout his career, Paul has served in leadership roles across both l

      8/20/24 8:00:00 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PepGen Inc.

      SC 13G/A - PepGen Inc. (0001835597) (Subject)

      11/14/24 4:31:29 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by PepGen Inc.

      SC 13G - PepGen Inc. (0001835597) (Subject)

      11/14/24 11:10:10 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PepGen Inc.

      SC 13G/A - PepGen Inc. (0001835597) (Subject)

      11/12/24 8:57:04 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen downgraded by BofA Securities with a new price target

      BofA Securities downgraded PepGen from Neutral to Underperform and set a new price target of $3.00

      12/16/24 12:07:01 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen downgraded by BofA Securities with a new price target

      BofA Securities downgraded PepGen from Buy to Neutral and set a new price target of $12.00

      7/31/24 11:28:59 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on PepGen with a new price target

      H.C. Wainwright initiated coverage of PepGen with a rating of Buy and set a new price target of $26.00

      12/21/22 9:28:36 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care